Archive · 23 May 2025
India's Battle Against Antimicrobial Resistance: Challenges and Solutions
Imagine tiny germs becoming super strong and not being killed by medicines (antibiotics) that doctors use.
That's antimicrobial resistance (AMR).
It's a growing problem in India, where antibiotics are sometimes misused.
A new medicine has been developed to treat infections but the current healthcare system faces issues such as diagnostic delays and gaps in communication.
Also, people often take antibiotics without a prescription.
The government is trying to fix this by spreading awareness, developing new plans, and keeping track of antibiotic use.
It's a big challenge, but everyone needs to work together to solve it.
Antimicrobial resistance (AMR) is a growing threat, with significant global impact, including a high death toll in India.
Overuse and misuse of antibiotics across sectors, including human medicine, livestock, and agriculture, contribute to AMR.
Wockhardt launched Nafithromycin ('Miqnaf'), a new antibiotic, the first in its class developed in India.
India faces challenges such as diagnostic delays, self-medication, and a lack of proper regulatory frameworks in its healthcare system.
The Indian government is implementing strategies such as establishing AMR surveillance networks, developing a National Action Plan, and promoting public awareness.
- Who
- Patients like Viswanathan, medical professionals, pharmaceutical companies (Wockhardt), and the Indian government are key stakeholders.
- What
- Antimicrobial resistance (AMR) is a growing problem, caused by the overuse of antibiotics. India is taking steps to address it, but faces challenges in its healthcare system.
- When
- AMR has been an issue, with research into and solutions being developed now.
- Where
- India and globally
- Why
- Overuse of antibiotics across sectors has led to increased resistance, posing a significant threat to public health.
- Global AMR Deaths (2019)
- 1.27 million
- India AMR Deaths (2019)
- 297,000
- Estimated Global AMR Deaths (2050)
- 1.91 million (direct); 8.22 million (associated)
- New Antibiotic
- Nafithromycin ('Miqnaf')
- Nafithromycin Success Rate
- 97%
- Key Challenge
- Diagnostic delays
- Government Action
- National Action Plan on AMR in 2017